Phase 4Active, not recruiting
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Sponsor
- Takeda (Industry)
- Enrollment
- 60 planned
- Conditions
- Ulcerative Colitis
- Interventions
- Vedolizumab; Tofacitinib
- Ages
- adults, older adults
- Registry
- NCT06095128
Full record on ClinicalTrials.gov
From the registry
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks. Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.
Primary outcomes
- Percentage of Participants Achieving Clinical Remission at Week 8 Based on Complete Mayo Score
History
Primary completion expected
Last registry update
Started
Registered
Papers citing this trial
- Advancing Equity and Patient Partnership in Clinical Trials for Inflammatory Bowel Disease: A Model for Inclusive Trial Design
Clinical and experimental gastroenterology